<DOC>
	<DOC>NCT00681356</DOC>
	<brief_summary>Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement</brief_summary>
	<brief_title>Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement</brief_title>
	<detailed_description>The purpose of this study is to evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing primary unilateral total knee arthroplasty</detailed_description>
	<criteria>Key Male or female aged 18 to 85 years with an American Society of Anesthesiologists (ASA) status of I, II, or III Planning to undergo primary unilateral Total Knee Arthroplasty (TKA) Key A body mass index (BMI) greater than 43 Known bleeding disorder or is taking agents affecting coagulation preoperatively Use of medications or a medical condition that in the investigator's opinion could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments Diabetes mellitus with a known HbA1C&gt;9.5 or a history of prolonged uncontrolled diabetes Previous knee arthroplasty (partial or total) of the same knee Participated in another clinical trial within 30 days prior to the planned TKA surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>TKA</keyword>
	<keyword>Total knee arthroplasty</keyword>
	<keyword>Total knee replacement</keyword>
	<keyword>Knee surgery</keyword>
</DOC>